Investing in the Brain: Why Neuroscience is the Next Oncology or Obesity
Registration
Sold Out
This event is sold out and no longer taking registrations.
About Event
95% of neuroscience drugs fail during clinical trials. Yet neuroscience has provided some of the biggest recent exits in biopharma: Karuna $14bn, Cerevel $9bn, Intra-Cellular $15bn. What has changed?
Join us to pick apart some commercial and scientific reasons to believe that now is the time to invest in neuroscience.
Location
Crick 1